A multicenter, randomized, controlled study of CO-1.01 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and low tumor expression of human equilibrative nucleoside transporter-1 (hENT1) determined by metastasis biopsy
| Autor: | Andrew R. Allen, Cynthia Voong, Mitch Raponi, Tone Ikdahl, E. Tomasetto, S. Jones, L. Smith, Irina Davidenko, Claudio Bassi, Lindsey Rolfe, Jeffrey D. Isaacson, Elizabeth Poplin, S. McLachlan |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty Pancreatic ductal adenocarcinoma Standard of care endocrine system diseases medicine.diagnostic_test biology business.industry medicine.disease Equilibrative nucleoside transporter 1 Gemcitabine Metastasis law.invention Oncology Randomized controlled trial law Biopsy Cancer research medicine biology.protein In patient business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 29:TPS144-TPS144 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | TPS144 Background: Gemcitabine (Gem) is standard of care therapy for mPDAC, however many patients do not benefit. Gem requires a transporter protein, hENT1, to enter cells. Reduced tumor hENT1 expr... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|